Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01229540
Other study ID # 08ZCGYSF01700
Secondary ID 08ZCGYSF01700
Status Terminated
Phase N/A
First received October 26, 2010
Last updated October 26, 2010

Study information

Verified date September 2008
Source Tianjin Medical University
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.


Recruitment information / eligibility

Status Terminated
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 45 Years to 74 Years
Eligibility Inclusion Criteria:

- T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) =7.0 mmol/L (=126 mg/dL), blood glucose =11.1 mmol/L (=200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose =11.1 mmol/L (=200 mg/dL).

- DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.

- All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion Criteria:

- Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Genetic:
genetic analyzer


Locations

Country Name City State
China Tianjin Eye Hospital, Clinical college of Ophthalmology ,Tianjin Medical Univercity Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University

Country where clinical trial is conducted

China,